Form D Don’t Lie: Deciphera Pharmaceuticals $90.60 million Financing. Michael D Taylor PhD Submitted Jul 13 form

Pharmaceuticals Deciphera Pharmaceuticals, Llc - Michael D Taylor PhD

Deciphera Pharmaceuticals Financing

Deciphera Pharmaceuticals, Llc, Limited Liability Company just released form D because of $90.60 million equity financing. The date of first sale was 2015-09-14. Deciphera Pharmaceuticals was able to fundraise $90.60 million. That is 100.00% of the financing round. The total financing amount was $90.60 million. The offering form was filed on 2016-07-13. The reason for the financing was: unspecified.

Deciphera Pharmaceuticals is based in Massachusetts. The company’s business is Pharmaceuticals. The SEC form was submitted by Michael D Taylor PhD President & CEO. The company was incorporated in 2015. The filler’s address is: 1601 Trapelo Road, Suite 152, Waltham, Ma, Massachusetts, 02451. Michael Taylor is the related person in the form and it has address: 1601 Trapelo Road, Suite 152, Waltham, Ma, Massachusetts, 02451. Link to Deciphera Pharmaceuticals Filing: 000165415116000002.

Analysis of Deciphera Pharmaceuticals Offering

On average, companies in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Deciphera Pharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Deciphera Pharmaceuticals is high? The average investment floor size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 16,195.69% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Deciphera Pharmaceuticals Also

The Form D signed by Michael D Taylor PhD might help Deciphera Pharmaceuticals, Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment